2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Ulf Landmesser (Lead / Corresponding author), M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J. F. Belch, Jan Borén, Michel Farnier, Brian A. Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Luscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto PintoLale Tokgozoglu, Jeroen J. Bax, Alberico L. Catapano

Research output: Contribution to journalComment/debate

100 Citations (Scopus)
77 Downloads (Pure)

Abstract

The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.
Original languageEnglish
Pages (from-to)1131-1143
Number of pages13
JournalEuropean Heart Journal
Volume39
Issue number14
Early online date16 Oct 2017
DOIs
Publication statusPublished - 7 Apr 2018

Fingerprint

Hyperlipoproteinemia Type II
Advisory Committees
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proprotein Convertase 9

Keywords

  • atherosclerosis

Cite this

Landmesser, Ulf ; Chapman, M. John ; Stock, Jane K. ; Amarenco, Pierre ; Belch, Jill J. F. ; Borén, Jan ; Farnier, Michel ; Ference, Brian A. ; Gielen, Stephan ; Graham, Ian ; Grobbee, Diederick E. ; Hovingh, G. Kees ; Luscher, Thomas F. ; Piepoli, Massimo F. ; Ray, Kausik K. ; Stroes, Erik S. ; Wiklund, Olov ; Windecker, Stephan ; Zamorano, Jose Luis ; Pinto, Fausto ; Tokgozoglu, Lale ; Bax, Jeroen J. ; Catapano, Alberico L. / 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. In: European Heart Journal. 2018 ; Vol. 39, No. 14. pp. 1131-1143.
@article{4da4a4829a2546f6b416312ca71f5f56,
title = "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia",
abstract = "The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.",
keywords = "atherosclerosis",
author = "Ulf Landmesser and Chapman, {M. John} and Stock, {Jane K.} and Pierre Amarenco and Belch, {Jill J. F.} and Jan Bor{\'e}n and Michel Farnier and Ference, {Brian A.} and Stephan Gielen and Ian Graham and Grobbee, {Diederick E.} and Hovingh, {G. Kees} and Luscher, {Thomas F.} and Piepoli, {Massimo F.} and Ray, {Kausik K.} and Stroes, {Erik S.} and Olov Wiklund and Stephan Windecker and Zamorano, {Jose Luis} and Fausto Pinto and Lale Tokgozoglu and Bax, {Jeroen J.} and Catapano, {Alberico L.}",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\circledC} The Author 2017.",
year = "2018",
month = "4",
day = "7",
doi = "10.1093/eurheartj/ehx549",
language = "English",
volume = "39",
pages = "1131--1143",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "14",

}

Landmesser, U, Chapman, MJ, Stock, JK, Amarenco, P, Belch, JJF, Borén, J, Farnier, M, Ference, BA, Gielen, S, Graham, I, Grobbee, DE, Hovingh, GK, Luscher, TF, Piepoli, MF, Ray, KK, Stroes, ES, Wiklund, O, Windecker, S, Zamorano, JL, Pinto, F, Tokgozoglu, L, Bax, JJ & Catapano, AL 2018, '2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia', European Heart Journal, vol. 39, no. 14, pp. 1131-1143. https://doi.org/10.1093/eurheartj/ehx549

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. / Landmesser, Ulf (Lead / Corresponding author); Chapman, M. John; Stock, Jane K.; Amarenco, Pierre; Belch, Jill J. F.; Borén, Jan; Farnier, Michel; Ference, Brian A.; Gielen, Stephan; Graham, Ian; Grobbee, Diederick E.; Hovingh, G. Kees; Luscher, Thomas F.; Piepoli, Massimo F.; Ray, Kausik K.; Stroes, Erik S.; Wiklund, Olov; Windecker, Stephan; Zamorano, Jose Luis; Pinto, Fausto; Tokgozoglu, Lale; Bax, Jeroen J.; Catapano, Alberico L.

In: European Heart Journal, Vol. 39, No. 14, 07.04.2018, p. 1131-1143.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

AU - Landmesser, Ulf

AU - Chapman, M. John

AU - Stock, Jane K.

AU - Amarenco, Pierre

AU - Belch, Jill J. F.

AU - Borén, Jan

AU - Farnier, Michel

AU - Ference, Brian A.

AU - Gielen, Stephan

AU - Graham, Ian

AU - Grobbee, Diederick E.

AU - Hovingh, G. Kees

AU - Luscher, Thomas F.

AU - Piepoli, Massimo F.

AU - Ray, Kausik K.

AU - Stroes, Erik S.

AU - Wiklund, Olov

AU - Windecker, Stephan

AU - Zamorano, Jose Luis

AU - Pinto, Fausto

AU - Tokgozoglu, Lale

AU - Bax, Jeroen J.

AU - Catapano, Alberico L.

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.

PY - 2018/4/7

Y1 - 2018/4/7

N2 - The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

AB - The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

KW - atherosclerosis

U2 - 10.1093/eurheartj/ehx549

DO - 10.1093/eurheartj/ehx549

M3 - Comment/debate

C2 - 29045644

VL - 39

SP - 1131

EP - 1143

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 14

ER -